Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Public ClinicalTrials.gov record NCT00590187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Study identification
- NCT ID
- NCT00590187
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cyclacel Pharmaceuticals, Inc.
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- Sapacitabine, Arm A Drug
- Sapacitabine, Arm B Drug
- Sapacitabine, Arm C Drug
- Sapacitabine, Arm D Drug
- Sapacitabine, Arm G Drug
- Sapacitabine, Arm H Drug
- Sapacitabine, Arm I Drug
- sapacitabine, Arm E Drug
- sapacitabine, Arm F Drug
Drug
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2007
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2018
- Last update posted
- Jun 3, 2024
2007 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| UCLA Division of Hematology-Oncology | Los Angeles | California | 90095 | — |
| Stanford Hospitals and Clinics | Stanford | California | 94305 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| The Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institiute | Buffalo | New York | 14263 | — |
| New York Medical College | Hawthorne | New York | 10532 | — |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt U Medical Center | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00590187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2024 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00590187 live on ClinicalTrials.gov.